Method of administration and treatment

Inventors

Beal, Ryan

Assignees

Dyve Biosciences Inc

Abstract

Provided herein are formulations for topical and/or transdermal administration, and methods of using these formulations for the treatment of proliferative diseases related to cancer such as cancers and related conditions, and solid tumors. Also provided are formulations for topical and/or transdermal administration, and methods of using these formulations for melasma, gout, skin disorders, and other diseases and disorders described herein as well as methods for modulating the pH (e.g. raising) of a tissue or microenvironment proximal to a tumor, modulating pH, or improving the effectiveness of know chemotherapeutic agents, immunotherapy and the like for the prevention, treatment of cancers and related conditions described herein.

Core Innovation

The invention relates to treating gout by administering a transdermal formulation comprising a buffering agent to a patient having abnormal levels of uric acid crystals in one or more joints, tendons or surrounding tissue. The formulation is administered in a manner that reduces the levels of uric acid crystals in the one or more joints, tendons or surrounding tissue, resulting in a reduction in the symptoms of gout. In particular embodiments, the buffering agent consists of sodium bicarbonate or sodium carbonate.

The disclosed formulations modify pH in the vicinity of the gout site through the buffering action of the buffering agent contained in the transdermal formulation. The document further describes raising pH in the vicinity of the gout site as part of the transdermal approach, with buffering and pH-modulating effects tied to reduced gout symptoms.

The disclosed formulations are described as topical/transdermal buffered carbonate or bicarbonate formulations with formulation components for delivery, including penetrant and detergent portions in a water-containing formulation. Additional components such as menthol are described, and the formulations are also described in dosage forms including cream, lotion, or ointment.

Claims Coverage

The provided excerpts include two independent claims, both directed to transdermal treatment of gout with a buffering agent. Across the independent claims, there are two buffering-agent limitations, with dependent refinements specifying formulation components and presentation.

The independent-claim coverage is directed to transdermal administration of a buffering agent to lower uric acid crystal levels in gout-associated joints, tendons, or surrounding tissue, with gout symptom reduction as the stated result. The buffering-agent specificity in the provided independent claims is limited to sodium bicarbonate or sodium carbonate, with dependent claims further constraining formulation components and dosage forms.

Stated Advantages

Documented Applications